Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified. In this retrospective multicentre observational study, based on a previous analysis that included 501 adult patients with severe AD (Eczema Area and Severity Index [EASI] ≥24 at baseline, contraindication, side-effects or failure in respect to cyclosporine according to the Italian Drug Agency [AIFA] recommendations) treated with dupilumab from ten Italian allergological/dermatological centres during September 2018-April 2020, we aimed at investigating patients’ baseline factors influencing treatment outcome and time to treatment response. No wash-out period was required. Any topical approved AD treatments were permitted as needed. Patients receiving systemic treatments during dupilumab therapy were excluded from the study.

Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response

Macchia, L;Di Bona, D;
2021-01-01

Abstract

Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified. In this retrospective multicentre observational study, based on a previous analysis that included 501 adult patients with severe AD (Eczema Area and Severity Index [EASI] ≥24 at baseline, contraindication, side-effects or failure in respect to cyclosporine according to the Italian Drug Agency [AIFA] recommendations) treated with dupilumab from ten Italian allergological/dermatological centres during September 2018-April 2020, we aimed at investigating patients’ baseline factors influencing treatment outcome and time to treatment response. No wash-out period was required. Any topical approved AD treatments were permitted as needed. Patients receiving systemic treatments during dupilumab therapy were excluded from the study.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11369/440530
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact